KING OF PRUSSIA, Pa. — 19 May 2017
CSL Behring received the National Organization for Rare Disorders’ (NORD) 2017 Industry Innovation Award last night in Washington, D.C. for pioneering new medicines. The biotech leader was recognized for developing its long-acting fusion protein for patients with hemophilia B.
“We are proud to present the team at CSL Behring with a 2017 Industry Innovation Award for the important work they are doing to address the needs of patients with hemophilia B,” said Peter L. Saltonstall, president and CEO of NORD. “This recognition underscores CSL Behring’s commitment to respond to the needs of people living with rare diseases.”
Debra Bensen-Kennedy, MD, CSL Behring’s Vice President for Medical Affairs, North America, accepted the award, which was presented by Meaghan Carty whose son has hemophilia B, on behalf of the company’s 14,000+ employees worldwide,
“With the introduction of IDELVION, we’re excited to build on a platform that we believe will transform replacement factor therapy for patients with bleeding disorders,” Dr. Bensen-Kennedy said.
“We’re especially thankful for the trust that physicians and patients place in us every day,” she continued. “And we’ll continue to develop better medicines that are resetting the expectations of people with rare diseases.”
NORD is a patient advocacy organization dedicated to individuals with rare diseases and the organizations that serve them. Along with its more than 260 patient organization members, NORD is committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and patient services.
About CSL Behring
CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn.
CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL), headquartered in Melbourne, Australia, employs more than 17,000 people, providing its life-saving, life-changing therapies to people in more than 60 countries. For more information visit www.CSLBehring.com and follow us on www.Twitter.com/CSLBehring.